Contributions of Interleukin-1 Receptor Signaling in Traumatic Brain Injury

Traumatic brain injury (TBI) in various forms affects millions in the United States annually. There are currently no FDA-approved therapies for acute injury or the chronic comorbidities associated with TBI. Acute phases of TBI are characterized by profound neuroinflammation, a process that stimulate...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in behavioral neuroscience 2020-01, Vol.13, p.287-287
Main Authors: Thome, Jason G, Reeder, Evan L, Collins, Sean M, Gopalan, Poornima, Robson, Matthew J
Format: Article
Language:English
Subjects:
Adapter proteins
astrocyte
Bans
Behavior
Binding sites
Clinical trials
Convulsions & seizures
cytokine
Cytokines
Disease control
Disease prevention
Drug therapy
FDA approval
IL-1β
Immune system
Inflammatory diseases
Interleukin 1
Interleukin 1 receptor antagonist
Interleukin 1 receptors
interleukin-1 receptor
Kinases
Localization
microglia
Neuroscience
Pituitary gland
Rheumatoid arthritis
Transcription factors
Trauma
Traumatic brain injury
Tumor necrosis factor-TNF
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Traumatic brain injury (TBI) in various forms affects millions in the United States annually. There are currently no FDA-approved therapies for acute injury or the chronic comorbidities associated with TBI. Acute phases of TBI are characterized by profound neuroinflammation, a process that stimulates the generation and release of proinflammatory cytokines including interleukin-1α (IL-1α) and IL-1β. Both forms of IL-1 initiate signaling by binding with IL-1 receptor type 1 (IL-1R1), a receptor with a natural, endogenous antagonist dubbed IL-1 receptor antagonist (IL-1Ra). The recombinant form of IL-1Ra has gained FDA approval for inflammatory conditions such as rheumatoid arthritis, prompting interest in repurposing these pharmacotherapies for other inflammatory diseases/injury states including TBI. This review summarizes the currently available preclinical and clinical literature regarding the therapeutic potential of inhibiting IL-1-mediated signaling in the context of TBI. Additionally, we propose specific research areas that would provide a greater understanding of the role of IL-1 signaling in TBI and how these data may be beneficial for the development of IL-1-targeted therapies, ushering in the first FDA-approved pharmacotherapy for acute TBI.
ISSN:1662-5153
1662-5153
DOI:10.3389/fnbeh.2019.00287